New Regimen Effective in Women With HIV-1

Dolutegravir-abacavir-lamivudine (DTG/ABC/3TC) combined treatment is safer and more effective than ritonavir-boosted atazanavir (ATV/r+FTC/TDF) in treating women with human immunodeficiency virus (HIV) type 1, according to new research.

To test the safety and efficacy of alternative treatments for this population, the researchers conducted the ARIA study in which 495 women with HIV-1 and an RNA level of 500 c/mL or more were randomly assigned to a once-daily DTG/ABC/3TC or ATV/r+FTC/TDF regimen for 48 weeks.
_________________________________________________________________________________________________________________________________________________________________________

RELATED CONTENT
Study: Preventive Ring Does Not Cause Drug Resistance in HIV
Children with Nonprogressing HIV Could Shed Light on New Treatment Strategies
_________________________________________________________________________________________________________________________________________________________________________

The researchers tracked participants’ RNA levels using a Snapshot algorithm and performed additional analyses on race subgroups.

After the 48-week follow-up, 82% of the DTG/ABC/3TC group had achieved an RNA level of less than 50 c/mL compared with 71% of the ATV/r+FTC/TDF group.

The DTG/ABC/3TC group also had lower rates of discontinuation due to adverse events and lower rates of Snapshot virologic failure than the ATV/r+FTC/TDF group.

Response rates were higher for those in the DTG/ABC/3TC group compared with the ATV/r+FTC group across all race subgroups.

“DTG/ABC/3TC demonstrated superior efficacy and a favorable safety profile compared to ATV/r+FTC/TDF in treatment-naïve women, after 48 weeks of treatment,” the researchers concluded. “Race subgroup analyses were consistent with overall results.”

—Amanda Balbi

Reference:
Hagins D, Dietz C, Jain M, et al. Efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed dose combination (FDC) compared with ritonavir boosted atazanavir (ATV/R) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naïve women with hiv-1 infection (ARIA study): analyses by race subgroups. Paper presented at: IDWeek 2016; October 26-30, 2016; New Orleans, LA. https://idsa.confex.com/idsa/2016/webprogram/Paper56539.html. Accessed October 31, 2016.